Use of polymorphic forms of rifaximin for medical preparations
DC CAFCFirst Claim
Patent Images
1. A method of treating bacterial infection in a patient suffering from a bowel related disorder comprising administering to a patient in need thereof a solid pharmaceutical composition comprising a therapeutically effective amount of one or more of Form α
- , Form β
, or Form γ
polymorph of rifaximin and a pharmaceutically acceptable excipient or carrier, wherein the amount of each of Form α
, Form β
, or Form γ
polymorph of rifaximin present in said pharmaceutical composition is an amount to control the amount of systemic absorption of said rifaximin,wherein the rifaximin Form α
has x-ray powder diffraction pattern peaks at about 7.4°
;
19.7°
;
21.0° and
22.1°
2-θ
,wherein the rifaximin Form β
has x-ray powder diffraction pattern peaks at about 5.4°
;
9.0°
; and
20.9°
2-θ
, andwherein the rifaximin Form γ
has x-ray powder diffraction pattern peaks at about 5.0°
, 7.1°
, and 8.4°
2-θ
.
3 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The present invention relates to Rifaximin polymorphic forms α, β and γ, to their use in medicinal preparations for the oral or topical route and to therapeutic methods using them.
-
Citations
30 Claims
-
1. A method of treating bacterial infection in a patient suffering from a bowel related disorder comprising administering to a patient in need thereof a solid pharmaceutical composition comprising a therapeutically effective amount of one or more of Form α
- , Form β
, or Form γ
polymorph of rifaximin and a pharmaceutically acceptable excipient or carrier, wherein the amount of each of Form α
, Form β
, or Form γ
polymorph of rifaximin present in said pharmaceutical composition is an amount to control the amount of systemic absorption of said rifaximin,wherein the rifaximin Form α
has x-ray powder diffraction pattern peaks at about 7.4°
;
19.7°
;
21.0° and
22.1°
2-θ
,wherein the rifaximin Form β
has x-ray powder diffraction pattern peaks at about 5.4°
;
9.0°
; and
20.9°
2-θ
, andwherein the rifaximin Form γ
has x-ray powder diffraction pattern peaks at about 5.0°
, 7.1°
, and 8.4°
2-θ
. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)
- , Form β
Specification